# GSK wins China approval for Blenrep in previously treated multiple myeloma

- Link: https://www.directorstalkinterviews.com/gsk-wins-china-approval-for-blenrep-in-previously-treated-multiple-myeloma/4121249382
- Published: 2026-04-20T07:21:16+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
NYSE: GSK) has announced the National Medical Products Administration (NMPA) of 
China has approved _Blenrep_ (belantamab mafodotin) in combination with bortezomib
and dexamethasone (BVd) for the treatment of adults with relapsed or refractory 
multiple myeloma who have received at least one prior line of therapy.

· Blenrep combination showed a 42% reduction in risk of death and nearly tripled
median progression-free survival versus a daratumumab-based triplet[1],[2]

· As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep provides
a new and needed mechanism of action in therapy1,[3]

· Blenrep is the only fully outpatient anti-BCMA therapy, minimising patient and
healthcare burden[4]

The approval follows priority review^([5]) of the application and Breakthrough Therapy
Designation^([6]) for the BVd combination based on its potential to provide substantial
improvement over available therapies.^([7])

The _Blenrep _approval is supported by data from the pivotal DREAMM-7 phase III 
trial. These include statistically significant and clinically meaningful progression-
free survival (PFS) and overall survival (OS) results for the _Blenrep_ combination
versus a daratumumab-based triplet combination with bortezomib and dexamethasone(
DVd). The safety and tolerability profiles of the _Blenrep_ combination were broadly
consistent with the known profiles of the individual agents.^(1)^(,)^(2)

> **Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said:**“
> Patients with multiple myeloma who face relapse need treatment options that are
> both effective and accessible. Today’s approval of _Blenrep_ brings anti-BCMA 
> therapy to patients in China with relapsed or refractory multiple myeloma in 2L
> +, introducing a differentiated mechanism of action with the potential to help
> slow disease progression and extend survival. Further, _Blenrep_ as the only anti-
> BCMA ADC is fully outpatient administered, so patients can be treated at any site
> of care without complex pre-administration regimens or hospitalisation.”

In China, the incidence of multiple myeloma has doubled to approximately 30,000 
new cases annually and mortality has increased by 50% over the past three decades.
^([8]) _Blenrep_ is the only anti-BCMA (B-cell maturation antigen) antibody-drug
conjugate (ADC) approved in multiple myeloma, which provides patients with a differentiated
mechanism of action. _Blenrep_ can be administered to a range of patient types across
treatment settings as a 30-minute outpatient infusion. 

[1] Hungria V, Robak P, Hus M et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone
for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090.
Epub 2024 Jun 1. PMID: 38828933.

[2] Hungria V, Robak P, H Marek, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone
Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma:
Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 
Trial. Presented at the 66th American Society of Hematology (ASH) Annual Meeting
and Exposition. December 2024.

[3] Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed and refractory
multiple myeloma. Blood. 2015;125(20). doi:10.1182/blood-2014-11-568923.

[4] Blenrep US Prescribing Information.

[5] GSK press release issued 9 December 2024. Blenrep (belantamab mafodotin) combination
accepted for priority review in China in relapsed/refractory multiple myeloma. Available
at: https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-
combination-accepted-for-priority-review-in-china-in-relapsedrefractory-multiple-
myeloma/.

[6] GSK press release issued 13 September 2024. Blenrep (belantamab mafodotin) in
combination receives Breakthrough Therapy Designation in China for treatment of 
relapsed/refractory multiple myeloma. Available at: https://www.gsk.com/en-gb/media/
press-releases/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-
therapy-designation-in-china-for-treatment-of-relapsedrefractory-multiple-myeloma/.

[7] China Drug Registration Regulation. Available at: http://www.gov.cn/gongbao/
content/2020/content_5512563.htm. Accessed 16 March 2026.

[8] Liu J, Liu W, Mi L, et al. Burden of multiple myeloma in China: an analysis 
of the Global Burden of Disease, Injuries, and Risk Factors Study 2019. Chin Med
J (Engl). 2023;136(23):2834-2838. Published 2023 Dec 5. doi:10.1097/CM9.0000000000002600.

Share on:
